Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
- Conditions
- HIVHIV Infections
- Interventions
- Registration Number
- NCT01815736
- Lead Sponsor
- Gilead Sciences
- Brief Summary
The primary objective of this study is to evaluate the non-inferiority of switching to a tenofovir alafenamide (TAF)-containing fixed dose combination (FDC) relative to maintaining tenofovir disoproxil fumarate (TDF)-containing combination regimens in virologically suppressed HIV-infected participants as determined by having HIV-1 RNA \< 50 copies/mL at Week 48.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1443
- Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
- Currently receiving antiretroviral therapy consisting of E/C/F/TDF, EFV/FTC/TDF, RTV+ATV+FTC/TDF, or COBI+ATV+FTC/TDF for ≥ 6 consecutive months preceding the final visit in their earlier study
- Completion of the Week 144 visit in studies GS-US-236-0102, GS-US-236-0103, GS-US-216-0114, or completion of the Week 96 visit in study GS-US-264-0110 (only participants on an EFV-based regimen), or completion of studies GS-US-236-0104, GS-US-216-0105
- Plasma human immunodeficiency virus type 1-ribonucleic acid (HIV-1 RNA) concentrations at undetectable levels for at least 6 consecutive months prior to the screening visit and have HIV RNA < 50 copies/mL at the screening visit
- Normal echocardiograph (ECG)
- Estimated glomerular filtration rate (GFR) ≥ 50 mL/min according to the Cockcroft-Gault formula for creatinine clearance
- Hepatic transaminases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) ≤ 5 × upper limit of the normal range (ULN)
- Direct bilirubin ≤ 1.5 x ULN
- Adequate hematologic function
- Serum amylase ≤ 5 × ULN
- Females of childbearing potential must agree to utilize highly effective contraception methods or be non-heterosexually active or practice sexual abstinence from screening throughout the duration of study treatment and for 12 weeks following the last dose of study drug if receiving EFV/FTC/TDF regimen, and 30 days for those assigned to all other regimens.
- Female participants who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing
- Female participants who have stopped menstruating for ≥ 12 months but do not have documentation of ovarian hormonal failure must have a serum follicle stimulating hormone (FSH) level at screening within the post-menopausal range based on the Central Laboratory reference range
Key
- A new acquired immunodeficiency syndrome (AIDS)-defining condition diagnosed within the 30 days prior to screening
- Hepatitis B surface antigen position
- Hepatitis C antibody positive
- Participants experiencing decompensated cirrhosis
- Females who are breastfeeding
- Positive serum pregnancy test
- Have an implanted defibrillator or pacemaker
- Current alcohol or substance use judged by the Investigator to potentially interfere with subject study compliance
- History of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma
- Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline
- Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements
- Participation in any other clinical trial without prior approval from the sponsor is prohibited while participating in this trial
- Participants receiving ongoing therapy with drugs not to be used with elvitegravir (EVG), COBI, FTC, TDF, ATV, RTV, EFV, and TAF or participants with any known allergies to the excipients of E/C/F/TDF, E/C/F/TAF, EFV/FTC/TDF, ATV, COBI, RTV, or FTC/TDF
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Stay on Baseline Treatment Regimen (SBR) E/C/F/TDF Randomized Phase: Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF) administered according to prescribing information for up to 96 weeks. Extension Phase: After completing 96 weeks of randomized treatment (SBR), all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF. Stay on Baseline Treatment Regimen (SBR) FTC/TDF Randomized Phase: Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF) administered according to prescribing information for up to 96 weeks. Extension Phase: After completing 96 weeks of randomized treatment (SBR), all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF. Stay on Baseline Treatment Regimen (SBR) ATV Randomized Phase: Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF) administered according to prescribing information for up to 96 weeks. Extension Phase: After completing 96 weeks of randomized treatment (SBR), all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF. Stay on Baseline Treatment Regimen (SBR) EFV/FTC/TDF Randomized Phase: Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF) administered according to prescribing information for up to 96 weeks. Extension Phase: After completing 96 weeks of randomized treatment (SBR), all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF. E/C/F/TAF E/C/F/TAF Randomized Phase: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) for up to 96 weeks. Extension Phase: After completing 96 weeks of randomized treatment, all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF. Stay on Baseline Treatment Regimen (SBR) COBI Randomized Phase: Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF) administered according to prescribing information for up to 96 weeks. Extension Phase: After completing 96 weeks of randomized treatment (SBR), all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF. Stay on Baseline Treatment Regimen (SBR) RTV Randomized Phase: Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF) administered according to prescribing information for up to 96 weeks. Extension Phase: After completing 96 weeks of randomized treatment (SBR), all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF.
- Primary Outcome Measures
Name Time Method Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Week 48 The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
- Secondary Outcome Measures
Name Time Method Percent Change From Baseline in Spine BMD at Week 48 Baseline; Week 48 Spine BMD was assessed by DXA scan. BMD is calculated as g/cm\^2; the mean (SD) percentage change is presented.
Change From Baseline in Serum Creatinine at Week 48 Baseline; Week 48 Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 Week 48 The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Change From Baseline in CD4 Cell Count at Weeks 96 Baseline; Week 96 The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 Week 96 The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Change From Baseline in the Overall EFV-related Symptom Assessment Score at Week 48 Baseline; Week 48 The mean (SD) change of the overall EFV-related symptom assessment score is presented. The overall symptom score (ranging from 0 to 20) is the sum of the individual symptom scores ranging from 0 (no symptoms) to 4 (most severe symptoms) from the 5 EFV-related symptom assessments (dizziness, trouble sleeping, impaired concentration, sleepiness, and abnormal or vivid dream). A negative change from baseline indicates improvement.
EFV-Related Symptom Analysis Set: participants who received EFV/FTC/TDF as prior treatment, received at least 1 dose of study drug, and completed EFV-related symptom assessments at the baseline visit and at least 1 postbaseline visit.Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48 Baseline; Week 48 The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 Baseline; Week 48 Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. BMD is calculated as grams per square centimeter (g/cm\^2); the mean (SD) percentage change is presented.
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96 Week 96 The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Trial Locations
- Locations (167)
University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Southwest Infectious Disease Clinical Research, Inc.
🇺🇸Dallas, Texas, United States
Sunnybrook Health Sciences Centre
🇨🇦Toronto, Ontario, Canada
Jeffrey Goodman Special Care Clinic
🇺🇸Los Angeles, California, United States
Anthony Mills MD Inc
🇺🇸Los Angeles, California, United States
Living Hope Clinical Foundation
🇺🇸Long Beach, California, United States
AHF Research Center
🇺🇸Beverly Hills, California, United States
Wohlfeiler, Piperato and Associates, LLC
🇺🇸Miami Beach, Florida, United States
Therafirst Medical Center
🇺🇸Fort Lauderdale, Florida, United States
Alameda County Medical Center
🇺🇸Oakland, California, United States
Midway Immunology and Research Center
🇺🇸Fort Pierce, Florida, United States
Chelsea Village Medical, PC
🇺🇸New York, New York, United States
Orange Coast Medical Group
🇺🇸Newport Beach, California, United States
NorthStar Medical Center
🇺🇸Chicago, Illinois, United States
Be Well Medical Center
🇺🇸Berkley, Michigan, United States
Broward Health/Comprehensive Care Center
🇺🇸Fort Lauderdale, Florida, United States
Gary J. Richmond,M.D.,P.A.
🇺🇸Fort Lauderdale, Florida, United States
Rosedale Infectious Diseases
🇺🇸Huntersville, North Carolina, United States
Tarrant County Infectious Disease Associates
🇺🇸Fort Worth, Texas, United States
New York Hospital Queens
🇺🇸Flushing, New York, United States
Ottawa Hospital
🇨🇦Ottawa, Ontario, Canada
Baystate Infectious Diseases Clinical Research
🇺🇸Springfield, Massachusetts, United States
Saint Michaels Medical Center
🇺🇸Newark, New Jersey, United States
Summa Health System
🇺🇸Akron, Ohio, United States
Palmetto Health Richland
🇺🇸Columbia, South Carolina, United States
AIDS Arms, Inc./ Peabody Health Center
🇺🇸Dallas, Texas, United States
Carolinas Medical Center-Myers Park
🇺🇸Charlotte, North Carolina, United States
The Research Institute
🇺🇸Springfield, Massachusetts, United States
Upstate ID Association
🇺🇸Albany, New York, United States
Howard Brown Health Center
🇺🇸Chicago, Illinois, United States
Montefiore Medical Center - AIDS Center
🇺🇸Bronx, New York, United States
University of NC AIDS Clinical Trials Unit
🇺🇸Chapel Hill, North Carolina, United States
Beth Israel Medical Center- Division of Infectious Diseases
🇺🇸New York, New York, United States
Ricky K. Hsu, MD
🇺🇸New York, New York, United States
ID Care
🇺🇸Hillsborough, New Jersey, United States
SouthWest CARE Center
🇺🇸Santa Fe, New Mexico, United States
East Carolina University
🇺🇸Greenville, North Carolina, United States
East Sydney Doctors
🇦🇺Darlinghurst, New South Wales, Australia
CHU Saint-Pierre University Hospital
🇧🇪Brussels, Belgium
Community Research Initiative of New England
🇺🇸Boston, Massachusetts, United States
Therapeutic Concepts, P.A.
🇺🇸Houston, Texas, United States
Research Access Network
🇺🇸Houston, Texas, United States
Peter Shalit, M.D.
🇺🇸Seattle, Washington, United States
La Playa Medical Group and Clinical Research
🇺🇸San Diego, California, United States
The Kinder Medical Group
🇺🇸Miami, Florida, United States
Hennepin County Medical Center
🇺🇸Minneapolis, Minnesota, United States
Duke University Health System
🇺🇸Durham, North Carolina, United States
Kaiser Permanente Medical Center, Clinical Trials Unit
🇺🇸San Francisco, California, United States
Gordon E. Crofoot MD PA
🇺🇸Houston, Texas, United States
Winnipeg Regional Health Authority - Health Sciences Centre Winnipeg
🇨🇦Winnipeg, Manitoba, Canada
Albany Medical College
🇺🇸Albany, New York, United States
Michael Keith Wensley, MD, Inc., A Medical Corporation
🇺🇸Costa Mesa, California, United States
Kaiser Permanente
🇺🇸Los Angeles, California, United States
Peter J Ruane, MD, Inc
🇺🇸Los Angeles, California, United States
Stanford University
🇺🇸Palo Alto, California, United States
Metropolis Medical Group
🇺🇸San Francisco, California, United States
Kaiser Permanente Hospital
🇺🇸San Leandro, California, United States
Whitman Walker Clinic
🇺🇸Washington, District of Columbia, United States
AIDS Research Consortium of Atlanta
🇺🇸Atlanta, Georgia, United States
Infectious Disease Specialists of Atlanta
🇺🇸Decatur, Georgia, United States
Atlanta ID Group, PC
🇺🇸Atlanta, Georgia, United States
Ruth M. Rothstein CORE Center
🇺🇸Chicago, Illinois, United States
Mercer University School of Medicine
🇺🇸Macon, Georgia, United States
University of Hawaii - Hawaii Center for AIDS
🇺🇸Honolulu, Hawaii, United States
Southampton Healthcare
🇺🇸Saint Louis, Missouri, United States
Saint Louis University
🇺🇸Saint Louis, Missouri, United States
South Jersey Infectious Disease
🇺🇸Somers Point, New Jersey, United States
North Shore University Hospital, Divison of Infectious Diseases
🇺🇸Manhasset, New York, United States
Garcia's Family Health Group
🇺🇸Harlingen, Texas, United States
DCOL Center for Clinical Research
🇺🇸Longview, Texas, United States
Premier Clinical Research
🇺🇸Spokane, Washington, United States
Clinical Alliance for Research & Education, Infectious Diseases (CARE-ID)
🇺🇸Annandale, Virginia, United States
Holdsworth House Medical practice
🇦🇺Darlinghurst, New South Wales, Australia
St Vincent's Hospital, Sydney
🇦🇺Darlinghurst, New South Wales, Australia
Taylor Square Private Clinic
🇦🇺Darlinghurst, New South Wales, Australia
Albion Street Centre
🇦🇺Surry Hills, New South Wales, Australia
SMZ Baumgartner Hoehe - Otto-Wagner-Spital
🇦🇹Vienna, Austria
São Paulo Secretaria da Saúde - Instituto De Infectologia Emilio Ribas
🇧🇷Sao Paulo, Brazil
Faculdade de Medicina do ABC
🇧🇷Santo Andre, Brazil
Instituto De Pesquisa Clinica Evandro Chagas - Fundação Oswaldo Cruz
🇧🇷Rio de Janeiro, Brazil
São Paulo Secretaria da Saúde - Centro de Referência e Treinamento em DST/AIDS
🇧🇷Sao Paulo, Brazil
Maple Leaf Research
🇨🇦Toronto, Ontario, Canada
McGill University Health Centre (MUHC) - Montral Chest Institute
🇨🇦Montréal, Quebec, Canada
Hôpital de La Croix Rousse
🇫🇷Lyon, France
CHU Hotel Dieu
🇫🇷Nantes, France
Archet 1 CHU de Nice - 6ème Niveau
🇫🇷Nice, France
Hôpital Saint Louis
🇫🇷Paris, France
Hopital Saint Antoine
🇫🇷Paris, France
Center for HIV and Hepatogastroenterology
🇩🇪Duesseldorf, Germany
Centre Hospitalier de Tourcoing
🇫🇷Tourcoing, France
EPIMED GmbH
🇩🇪Berlin, Germany
Universitätsklinikum Frankfurt
🇩🇪Frankfurt am Main, Germany
University of Bonn
🇩🇪Bonn, Germany
Infektio Research GmbH / Infektiologikum Frankfurt
🇩🇪Frankfurt am Main, Germany
University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit
🇩🇪Hamburg, Germany
Universitatsklinikum Freiburg
🇩🇪Freiburg, Germany
ICH Study Center Hamburg
🇩🇪Hamburg, Germany
University of Cologne, Department of Internal Medicine
🇩🇪Köln, Germany
MUC Research GmbH
🇩🇪München, Germany
Azienda Ospedaliera Luigi Sacco 1° Divisione Malattie Infettive
🇮🇹Milano, Italy
Fondazione Centro San Raffaele del Monte Tabor
🇮🇹Milan, Italy
Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani" IRCCS
🇮🇹Rome, Italy
Comprensorio Amedeo Di Savoia Birago Di Vische
🇮🇹Torino, Italy
VA Caribbean Healthcare System
🇵🇷San Juan, Puerto Rico
Hospital Virgen del Rocio
🇪🇸Sevilla, Spain
Hospital Universitari De Bellvitge
🇪🇸Barcelona, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Centre Hospitalier Universitaire Vaudois
🇨🇭Lausanne, Switzerland
Brighton and Sussex University Hospitals NHS Trust
🇬🇧Brighton, United Kingdom
Chelsea and Westminster Hospital Foundation Trust
🇬🇧London, United Kingdom
Barts and the London NHS Trust
🇬🇧London, United Kingdom
Courtyard Clinic, St. Georges Hospital
🇬🇧London, United Kingdom
North Manchester General Hospital
🇬🇧Manchester, United Kingdom
Epidemiklinikken 5112, Rigshospitalet
🇩🇰Copenhagen, Denmark
Södersjukhuset
🇸🇪Stockholm, Sweden
Capital Medical Associates, PC
🇺🇸Washington, District of Columbia, United States
Greenwich Hospital
🇺🇸Greenwich, Connecticut, United States
Hospital de Santa Maria
🇵🇹Lisbon, Portugal
Health for Life Clinic PLLC
🇺🇸Little Rock, Arkansas, United States
Dupont Circle Physicians Group
🇺🇸Washington, District of Columbia, United States
Medizinische Universitat Wien
🇦🇹Vienna, Austria
Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde"
🇲🇽Guadalajara, Mexico
Erasmus MC
🇳🇱Rotterdam, Netherlands
Servico De Doencas Infecciosas - Hospital De Sao Joao
🇵🇹Porto, Portugal
HOPE Clinical Research
🇵🇷San Juan, Puerto Rico
Maharaj Nakorn Chiang Mai University, Faculty of Medicine, Department of Medicine
🇹🇭Chiang Mai, Thailand
Jacobi Medical Center
🇺🇸Bronx, New York, United States
Melbourne Sexual Health Clinic
🇦🇺Carlton, Victoria, Australia
George Washington University Medical Faculty Associates
🇺🇸Washington, District of Columbia, United States
Hôpital Universitaire Erasme - ULB
🇧🇪Ghent, Belgium
Ubc Downtown I.D. Clinic
🇨🇦Vancouver, British Columbia, Canada
Universitätsklinik für Infektiologie, Universitätsspital Bern
🇨🇭Bern, Switzerland
Medizinische Universität Graz
🇦🇹Graz, Austria
Clinique medicale l'Actuel
🇨🇦Montreal, Quebec, Canada
Alfred Hospital
🇦🇺Melbourne, Victoria, Australia
Northside Clinic
🇦🇺Melbourne, Victoria, Australia
Clinique Medicale du Quartier Latin
🇨🇦Montreal, Quebec, Canada
Clinique OPUS
🇨🇦Montreal, Quebec, Canada
Prahran Market Clinic
🇦🇺South Yarra, Victoria, Australia
Instituto Dominicano de Estudios Virologicos - IDEV
🇩🇴Santo Domingo, Dominican Republic
Clinical Research Puerto Rico
🇵🇷San Juan, Puerto Rico
HIV-NAT, Thai Red Cross AIDS Research Center and Faculty of Medicine Chulalongkorn University
🇹🇭Bangkok, Thailand
Onze Lieve Vrouwe Gasthuis, Afdeling Infectieziekten
🇳🇱Amsterdam, Netherlands
University Hospital of Zurich
🇨🇭Zürich, Switzerland
Ramathibodi Hospital, Mahidol University
🇹🇭Bangkok, Thailand
Siriraj HospitalDepartment of Preventive and Social Medicine, Faculty of Medicine
🇹🇭Bangkok, Thailand
Khon Kaen University
🇹🇭Khon Kaen, Thailand
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Southwest Center for HIV/AIDS
🇺🇸Phoenix, Arizona, United States
Spectrum Medical Group
🇺🇸Phoenix, Arizona, United States
Apex Research LLC
🇺🇸Denver, Colorado, United States
Henry Ford Health System
🇺🇸Detroit, Michigan, United States
Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
University Health Network, Toronto General Hospital
🇨🇦Toronto, Ontario, Canada
University of South Florida HIV Clinical Research Unit / Hillsborough County Health Department
🇺🇸Tampa, Florida, United States
Infectious Disease Research Institute Inc.
🇺🇸Tampa, Florida, United States
St. Joseph's Comprehensive Research Institute
🇺🇸Tampa, Florida, United States
East Bay AIDS Center
🇺🇸Oakland, California, United States
Greiger Clinic
🇺🇸Mount Vernon, New York, United States
Central West Clinical Research
🇺🇸Saint Louis, Missouri, United States
University of California, Davis Medical Center
🇺🇸Sacramento, California, United States
Kaiser Permanente Medical Group
🇺🇸Sacramento, California, United States
Yale University HIV Clinical Trials Program
🇺🇸New Haven, Connecticut, United States
Orlando Immunology Center
🇺🇸Orlando, Florida, United States
IDOCF/ Value Health MD, LLC
🇺🇸Orlando, Florida, United States
Bichat Hospital
🇫🇷Paris, France
Thomas Jefferson University
🇺🇸Philadelphia, Pennsylvania, United States